OTX-2002
omega Theraputics
$omga omega therapeutics presents new preclinical data supporting the first epigenomic controller, otx-2002, as a potential therapeutic approach in hepatocellular carcinoma at the esmo 2022 world congress on gastrointestinal cancer 
GetOnTrade is a news platform to help you stay up-to-date with the latest stock market news. We are not financial advisor(please do your own due diligence).